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rupture or erosion of an unstable atherosclerotic plaque. Rapid 
restoration of fl ow in the infarct-related coronary artery is of paramount 
importance to limit the infarct size. Thus primary PCI has become the 
standard of care in appropriate settings and defi nitive goals have been 
set in the form of Door-to-Balloon time of less than 90 minutes for 
primary PCI and Door-to-Needle time of less than 60 minutes for 
fi brinolytic therapy.(1) The South African situation is similar to that in 
many parts of the world, in that only a small percentage of patients 
presenting with a STEMI will be treated with primary PCI. The major 
reason is the limited availability of facilities in South Africa that can offer 
primary PCI. Fibrinolysis is therefore still the primary form of reperfusion 
therapy in the majority of patients. Thus in the South African context, 
issues of improvement of fi brinolytic therapy by adjunctive PCI, rescue 
PCI and late PCI are important. However, this is the subject matter of 
another review in this journal.
UA/NSTEMI differs from STEMI in that it is associated with a subtotal 
occlusion of the epicardial coronary artery, with some, albeit insuffi cient, 
fl ow past the unstable plaque and intra-luminal thrombus. Current 
guidelines suggest that patients presenting with UA/NSTEMI who have 
persistent or recurrent angina with / without ST-segment changes 
(≥2mm) or deep negative T-wave inversion despite optimal medical 
therapy; patients with signs of heart failure or hemodynamic instability; 
or life-threatening arrhythmias should be referred for urgent angio-
graphy / revascularization.(1) These patients, however, comprise only 
2-15% of the patients admitted to hospital with UA/NSTEMI. It is the 
management of the remaining large group of ACS patients that is up 
for debate.
 Two different treatment strategies may be followed after initial medical 
stabilization of UA/NSTEMI patients who do not meet the criteria for 
urgent angiography / revascularization. The fi rst is an early invasive 
(routine) strategy of coronary angiography and, if indicated, 
revascularization. The second is a conservative (selective invasive) 
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 Acute Coronary Syndrome (ACS) 
comprises three related disorders. In ST-elevation 
myocardial infarction (STEMI) rapid restoration of fl ow in 
the infarct-related artery (via pharmacological or 
mechanical means) is of paramount importance to 
minimize necrosis. In patients presenting with Unstable 
Angina / Non-ST-segment myocardial infarction (UA/
NSTEMI) the correct choice of the initial treat-
ment strategy (early invasive vs. selective invasive vs. 
conservative) is imperative in assuring optimal patient 
outcomes. Various risk prediction models can assist in the 
decision making process in an individual patient.  The timing 
of angiography and revascularization in patients selected 
for the early invasive strategy are important factors in 
determining the long-term outcome in this patient 
population subset.  SAHeart 2008; 5:58-64
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INTRODUCTION                                                                  
Acute Coronary Syndrome (ACS) comprises three related disorders: 
ST-elevation myocardial infarction (STEMI), unstable angina (UA), and 
non-ST-elevation myocardial infarction (NSTEMI). The initial management 
of STEMI differs considerably from that of UA and NSTEMI, which is 
generally considered as one clinical entity (UA/NSTEMI).  STEMI, which 
is responsible for 25% of ACS cases, occurs as a result of total occlusion 
of an epicardial coronary artery by an intra-luminal thrombus after 
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strategy in which patients, after appropriate medical stabilization, 
undergo coronary angiography and revascularization only if there is 
evidence of recurrent ischemia, e.g. recurrent infarction, angina at rest, 
dynamic ST-segment changes on ECG or inducible ischemia. Two 
alternatives for the invasive approach have emerged:  early (“immediate”) 
or deferred angiography, i.e. after a 12 to 48-hour window from 
symptom onset.
The choice of strategies has led to many debates at conferences and in 
the literature and there is widespread variation in procedure use among 
individual clinicians, institutions and countries.(2) Proponents of the early 
invasive strategy argue that the early determination of coronary 
anatomy can be used to tailor therapy, avoid lengthy hospital stay and 
prevent further ischemic events. Proponents of the conservative 
strategy argue that medical therapy can stabilize patients and that non-
invasive testing can identify patients at risk of future events and thus 
identify patients who would most benefi t from invasive intervention. 
Thereby, the costs and complications of invasive procedures can be 
minimized by using these modalities selectively. The last argument is 
particularly relevant to our own practice environment in South Africa, 
where resources are limited, especially in the public sector. Over the 
last decade many randomized trials and large scale registries have been 
published on this topic. The evidence for the relative benefi t or harm of 
these two approaches, as well as patient selection for the respective 
strategies and optimal timing for coronary angiography is the subject of 
this review. 
CHOICE OF STRATEGY                                                                                           
A meta-analysis of seven randomized trials (including early studies prior 
to the widespread use of stents and multi-drug adjunctive therapy) 
conducted by Metha et al., consisting of 9 212 patients, evaluated the 
benefi ts and risks of early invasive vs. selective invasive strategies in 
UA/NSTEMI over a mean follow-up period of 17 months.(3) Overall, 
death or MI was reduced from 14.4% in the selective invasive group to 
12.2% in the early invasive group (odds ratio [OR], 0.82; p < 0.001). This 
was largely driven by a signifi cant reduction in MI (9.4% vs. 7.3%; 
OR, 0.75; p < 0.001). There was a non-signifi cant trend toward a 
lower mortality with the early invasive strategy (6.0% vs. 5.5%; OR, 0.92; 
p < 0.33).
The early invasive strategy was, however, associated with a signifi cantly 
higher early mortality 1.8% vs. 1.1% for early vs. selective invasive, 
respectively (OR 1.60; p < 0.007) and the composite of death or MI 
(5.2% vs. 3.8%; OR 1.36; p < 0.002). The benefi cial effect of the early 
invasive strategy was actually achieved from hospital discharge to the 
end of follow-up (17 months) where the early invasive strategy was 
associated with fewer subsequent deaths (3.8% vs. 4.9%; p < 0.01) and 
the composite of death or MI (7.4% vs. 11.0%;  p<0.001). At the end of 
follow-up, there was also a 33% reduction in severe angina (11.2% vs. 
14.0%) and a 34% reduction in rehospitalization (32.5% vs. 41.3%) in 
patients who were stratifi ed to the early invasive strategy.(3)
A clue to risk stratifi cation was provided by the biomarker data.  Higher 
risk patients with elevated cardiac biomarkers at baseline benefi ted 
more from early invasive intervention, with no signifi cant benefi t 
observed in lower-risk patients with negative baseline biomarker 
levels. 
The ICTUS trial(4) was not included in the meta-analysis, as its results 
were published after the publication of the Mehta et al. meta-analysis. 
The results of the ICTUS trial challenged the paradigm of a superior 
outcome of an early invasive strategy. In this trial 1 200 high-risk ACS 
patients (troponin positive) were randomly assigned to either an early 
invasive (angiography within 24 to 48 hours) or a selectively invasive 
strategy. All patients received optimal medical therapy that included 
aspirin, clopidogrel, enoxaparin, abciximab during PCI and high dose 
statins. In this trial there was no difference in the primary composite 
end-point of death, MI, or rehospitalization for angina at 1 year (22.7% 
vs. 21.2%; p=0.33) with an early vs. selective invasive strategy. Mortality 
at one year was identical at 2.5%. In keeping with previous studies, early 
intervention was associated with a signifi cant early hazard of MI (15.0% 
vs. 10.0%; RR 1.5 p <0.005). Furthermore, the point estimate for the 
relative risk of the composite primary end point of death, MI or 
rehospitalization for angina favoured patients assigned to the selective 
invasive group for the entire follow-up period of 1 year. The long-term 
follow-up data of the ICTUS study cohort was recently published.(5) 
The primary composite endpoint was 30% in the early invasive group 
and 26% in the selective invasive group (p=0.09). No difference in 
overall cardiovascular mortality was noted between early invasive and 
selective invasive strategies (4.5% vs 5.0% p=0.97).
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The discrepancy between the ICTUS study and the results of the Mehta 
meta-analysis could, in part, be attributed to the relatively high rates of 
revascularization in the two study groups of the ICTUS trial (76% in 
the invasive and 40% in the selective invasive group).(4) Another 
factor could be that all patients in the ICTUS study received intensive 
medical therapy.
One of the weaknesses cited of the meta-analysis by Mehta et al. was 
that many of the trials included in the analysis were not contemporary 
to current clinical practice. In four of the trials, namely TIMI-3B,(6) 
VANQWISH.(7) MATE,(8) and FRISC-2,(9) the use of stents and GP IIb/
IIIa inhibitors was low or non-existent. However, a recent review of the 
more contemporary trials by the Cochrane collaboration confi rmed 
the initial observations reported by Mehta et al. In this systematic 
review, which included the ICTUS trial, mortality during initial 
hospitalization showed a trend to hazard with an early invasive strategy 
(RR, 1.59; 95% CI, 0.96-2.64).(10) However, late mortality, at 2-5 year 
follow-up was signifi cantly decreased by 25% (RR 0.75; p=0.09) with an 
early invasive strategy as compared to the conservative strategy. It must 
be noted, however, that this analysis was done prior to the publication 
of the 3-year data of the ICTUS study, which found no difference in 
mortality at 3 years follow-up.(5) The incidence of refractory angina was 
also signifi cantly reduced by 33% (RR 0.67 CI, 0.55-0.83) with an 
invasive strategy at 6-12 months. An early invasive strategy also further 
reduced the rehospitalization rates, with a relative risk of 0.67 (95% CI, 
0.61-0.74) at 6-12 months. The early invasive strategy, however, was 
associated with a two-fold increase in the relative risk of peri-procedural 
MI and a 1.7-fold increase in the relative risk of bleeding.  
The most recent meta-analysis published on the subject included 7 
studies comprising 8 375 patients.(11) These studies refl ect contemporary 
practice in that all patients received aspirin, unfractionated or low 
molecular weight heparin. Glycoprotein IIb/IlIa inhibitors were available 
during PCI in 6 of the 7 trials and thienopyridines were used as an 
adjunct to PCI in all trials. For the primary outcome of all-cause 
mortality at a mean follow-up of 2 years there was a signifi cant risk 
reduction for all-cause mortality from 6.5% for the conservative 
strategy  to 4.9% for an early invasive strategy (RR, 0.75; p=0.001), 
without an excess of early death (Figure 1). The analysis of all-cause 
mortality showed no heterogeneity between studies. Interestingly the 
analysis of mortality demonstrated that with longer follow-up, the 
mortality benefi t increased. Thus the risk reduction at 1 month was 
18%, at 6 months 17%, at 12 months 20% and at 2 years 25%. 
Furthermore, the incidence of non-fatal MI at 2-year follow-up was 
lower with the early invasive versus the conservative approach 
(7.6% vs. 9.1% p=0.012) again without an excess of early non-fatal MI 
(Figure 2). Long-term mortality reduction has further been confi rmed 
in the 5-year follow-up data of the RITA-3(12) trial and the 2-year follow-
up data of the FRISC-2 trial.(9) However, it must be noted that the long-
term follow-up at 3 years of the ICTUS study showed no mortality 
difference between the two treatment strategies.(5)
FIGURE 1:  Relative risk of all-cause mortality in NSTEMI 
Adapted from: Bavry AA et al. Benefi t of Early Invasive Therapy in Acute Coronary Syndromes. 
J Am Coll Cardiol 2006; 48: 1319-25
Frisc II 
TIMI-18
RITA-3
ISAR-COOL
ICTUS
Overall RR 0.75 (0.63-0.90)
Favours Early 
Invasive therapy
0.1 1 1.0Favours Conservative 
therapy
FIGURE 2:  Relative risk of recurrent non-fatal myocardial infarction in NSTEMI
Adapted from: Bavry AA et al. Benefi t of Early Invasive Therapy in Acute Coronary Syndromes. 
J Am Coll Cardiol 2006; 48: 1319-25
Frisc II 
TIMI-18
RITA-3
ISAR-COOL
ICTUS
Overall RR 0.83 (0.72-0.96)
Favours Early 
Invasive therapy
0.1 1 1.0Favours Conservative 
therapy
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Based on the above evidence, it is reasonable to conclude that in 
patients with UA/NSTEMI, a routine early invasive strategy is preferable 
to a selective invasive strategy in reducing major adverse cardiovascular 
events as well as severe angina and rehospitalization. However, it 
appears that the major benefi t of an early invasive strategy resides in 
reducing cardiovascular events over the long term with the risk that this 
strategy may be associated with an early hazard of myocardial infarction. 
Therefore, future strategies should focus on ways of reducing the early 
hazard and enhancing the later benefi ts of a routine invasive strategy.(3)
It is also important to note that in almost all the randomized trials, a 
signifi cant proportion of patients in the conservative arm eventually 
underwent revascularization (“crossover”), such that the benefi t of 
revascularization may have been underestimated.(10)
TIMING OF INVASIVENESS                                               
With the exception of indications for emergency / urgent angiography 
and revascularization, controversy remains as to the optimal timing 
between hospital admission, initiation of medical therapy, and the 
invasive evaluation.
Support for immediate angiography comes from the ISAR-COOL 
trial.(13) In this trial, 410 consecutive, high-risk NSTEMI patients were 
treated with intensive medical therapy; including aspirin, heparin, 
clopidogrel (600mg loading dose), and the Glycoprotein IIb/IlIa inhibitor, 
tirofi ban. Patients were randomized to immediate angiography (on 
average 2.4 hours after admission) or delayed angiography after a 
prolonged “cooling off ” period before catheterization (86 hours after 
admission and medical therapy).  Patients randomized to immediate 
PCI had a lower incidence of death or MI at 30 days than patients 
randomized to deferred PCI (5.9% vs. 11.6% p=0.04). Likewise, no early 
hazard was observed in the TACTICS-TIMI-18 study wherein patients 
were treated with upstream Glycoprotein IIb/IlIa inhibitor and where 
the mean delay to PCI was 22 hours.(14)
At variance with these fi ndings, are the results of the ICTUS trial, which 
showed that early routine invasive strategy within 48 hours after 
randomization was associated with an excess of MI.(4) Expedited 
catheterization was also associated with worse outcome in the 
FRISC-2(9) study as well as in the CRUSADE registry.(15)
Accordingly, current data does not mandate a systematic approach 
of immediate angiography in UA/NSTEMI patients stabilized with 
contemporary medical therapy. Both the ESC(1) and ACC/AHA(16) 
guidelines for the management of patients with UA/NSTEMI suggest 
that angiography / revascularization can be performed safely within 4 to 
72 hours of admission provided the patient is stabilized with optimal 
medical therapy.
SELECTION OF THE INITIAL TREATMENT STRATEGY 
BASED ON RISK FACTORS
The primary objective in selecting a treatment strategy in UA/NSTEMI 
is to yield the best long-term clinical outcome. In the individual patient 
the risk or hazard of an early invasive angiography / revascularization 
should be weighed against the long-term benefi t accrued from such a 
strategy. Risk stratifi cation is an integral component of managing patients 
presenting with UA/NSTEMI. The goal of risk stratifi cation is to identify 
patients with a high likelihood of an early complicated outcome who 
are at risk of recurrent coronary events or premature death and to 
offer such patients the benefi t of early angiography and revascularization. 
Patients presenting with persistent or recurrent ischemia, hemodynamic 
or electrical instability, or heart failure have a particularly high risk for 
major adverse cardiovascular events, and therefore benefi t from urgent 
angiography with revascularization (PCI or CABG).
The current guidelines(1,16) recommend the use of several parameters 
for risk stratifi cation for patients presenting with UA/NSTEMI, e.g. the 
TIMI(17) risk score (Table 1) or GRACE(18) risk score (Table 2). Patients 
presenting with moderate to high risk features according to one of 
these scoring systems also attain signifi cant benefi t from an early / 
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routine invasive strategy. The recently published guidelines(1) emphasize 
that patients with characteristics as listed in Table 3, be classifi ed as 
intermediate to high risk for major adverse cardiovascular events in the 
foreseeable future and should be submitted to an early invasive 
strategy.
Coronary angiography, by its very nature, risk stratifi es patients. Not 
only does it defi ne the degree and extent of coronary artery disease 
and thus the risk for recurrent events or mortality; but it is also a way 
of determining left ventricular function which in itself is a strong 
predictor of outcome in a wide spectrum of patients. Angiography is 
therefore clearly an important tool in the clinical decision making of 
patients with ACS.
  
TABLE 2: GRACE Risk Score for UA/NSTEMI(18)
    Points
Age (years)    
< 40 0   
40-49 18   
50-59 36   
60-69 55   
70-79 73   
≥80 91
Heart rate (bpm)    
<70  0   
70-89 7  
90-109 13 
110-149 23  
150-199 36  
>200 46
Systolic BP (MMHg)    
<80  63   
80-99 58   
100-119 47   
120-139 37   
140-159 26   
160-199 11   
>200 0
Creatinine (mmol/l)    
0-35  2   
35-70 5   
71-105 8   
106-140 11   
141-176 14   
177-353 23   
>354 31
Killip Class    
I    0   
II    21   
III    43   
IV    64
Cardiac Arrest at admission 43
Elevated cardiac marker 15
ST-segment deviation 30
Grace Risk Score:
Low  1 – 108
Intermediate 109 -140
High  141 - 372
  
TABLE 3: Characteristics associated with intermediate to high risk of an adverse 
cardiac event in patients with UA/NSTEMI(1)
Elevated troponin levels
Dynamic ST- or T-wave changes (symptomatic or silent)
Diabetes mellitus
Renal dysfunction (GFR < 60 ml/min/1.73m2)
Reduced left ventricular function (EF<40%)
Early post-infarction angina
Prior MI
PCI within 6 months
Prior CABG
Intermediate to high TIMI / GRACE risk score
TABLE 1: TIMI Risk Score for UA/NSTEMI(17)
Age ≥ 65 years
≥ CAD risk factors
Known CAD (>50% stenosis)
Prior Aspirin 
2 Anginal episodes in the preceding 24 hours
ST deviation ≥ 0.5mm 
Raised cardiac biomarkers
TIMI Risk Score
Low 0-2
Intermediate  3-4
High 5-7 
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On the other end of the spectrum is the low risk patient group in 
whom an early invasive strategy may be detrimental. This group of 
patients is equally well served with a conservative strategy or an elective 
angiography / revascularization should they have high risk features on 
non-invasive testing.
CONCLUSION                                                                    
There is sound evidence-based data that patients presenting with 
UA/NSTEMI, with the exception of the low risk group, will benefi t from 
an early invasive strategy (within 4 to 72 hours of admission and 
stabilization with evidence-based medical therapy) with regard to 
reduced long-term rates of death and non-fatal MI.  Trials that performed 
very early angiography (mean 9 hours) do not have an advantage in 
long-term survival as compared to trials that performed delayed 
angiography (mean of 39 hours).(11) A large percentage of patients who 
undergo angiography also get revascularized. Thus the timing of 
angiography may not necessarily be the most important variable and 
revascularization may be the more critical factor in determining long-
term outcome.
An important lesson from the ICTUS trial is the importance of 
optimized medical treatment in the management of patients with UA/
NSTEMI. In the conservative arm of the study, 94% of patients were on 
statin therapy and 50% on clopidogrel at the time of discharge. Both 
these agents have been shown to reduce cardiac events in the 
management of UA/NSTEMI. It has been suggested that the neutral 
outcome of the ICTUS trial was related to the very high rates of 
optimal medical therapy in the two groups of patients.(19)
Future research needs to clarify the optimal timing of the invasive 
approach and to determine additional strategies for minimizing the 
early hazard of angiography. Research also needs to ascertain whether 
additional risk stratifi cation will help in determining the best approach 
to an individual patient with UA/NSTEMI.
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